Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis.
Astrocytes in multiple sclerosis.
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.
Further Understanding of the Immunopathology of Multiple Sclerosis: Impact on Future Treatments.
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Sunshine, Sea, and Season of Birth: MS Incidence in Wales.
Best Practices and Key Challenges in Cost-Effectiveness Modelling of Multiple Sclerosis Therapies.
Analysis of the Recent HTA Decision Making Landscape for Multiple Sclerosis Therapies - Trends and Future Opportunities.
Newly Identified Gait Patterns in Patient With Multiple Sclerosis May Be Related to Push-Off Quality.
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Development of oral immunomodulatory agents in the management of multiple sclerosis.
Improving Clinical Outcomes and Health Care Resources Utilization in Multiple Sclerosis: A Portuguese Hospital Perspective.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Histamine and Immune Biomarkers in CNS Disorders.
Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis.
Masitinib mesylate application for conditional approval
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy.
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Preferred sources of health information in persons with multiple sclerosis: degree of trust and information sought.
Effect of therapeutic horseback riding on balance and gait of people with multiple sclerosis.
Olfactory dysfunction in patients with multiple sclerosis.
Difficulties in adjustment to multiple sclerosis: vulnerability and unpredictability of illness in the foreground.
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.